Proteomic Analysis in Cancer Patients

  • Yasuhiro Kuramitsu
  • Kazuyuki Nakamura
Part of the Cancer Drug Discovery and Development™ book series (CDD&D)


The term proteome means the total protein complement of a genome, and proteomics means the analysis for proteome. The combination of two-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS) is a proteomic method of high-throughput analysis of protein expression. By using this 2-DE and MS, proteomic studies have identified many proteins that may be involved in the pathogenic mechanism of cancers. These studies analyzed cancer cell lines, as well as cancer tissues or serum from patients.

In the present study, we analyzed proteome in hepatocellular carcinoma (HCC), esophageal cancer, and pancreatic cancer tissues. We identified many proteins whose expression in cancer tissues was different from corresponding non-cancerous tissues by using 2-DE and MS. Furthermore, we identified some auto-antibodies reacting to proteins in HCC cancer tissues. In this chapter, we will describe the method, our experimental result, and reports from other researchers about proteomic analysis in cancer patients.

Key Words

Proteomics hepatocellular carcinoma HCC esophageal cancer pancreatic cancer auto-antibody 


  1. 1.
    Wasinger VC, Cordwell SJ, Cerpa–Poljak A et al. Progress with gene–product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 1995;16:1090–1094.CrossRefPubMedGoogle Scholar
  2. 2.
    O'Farrell PH. High resolution two-dimensional electrophoresis of proteins.J Biol Chem 1975; 250:4007–4021.PubMedGoogle Scholar
  3. 3.
    Simpson RJ, Connolly LM, Eddes JS et al. Proteomic analysis of the human colon carcinoma cell line (LIM 1215): development of a membrane protein database. Electrophoresis 2000;21:1707–1732.CrossRefPubMedGoogle Scholar
  4. 4.
    Ha GH, Lee SU, Kang DG et al. Proteome analysis of human stomach tissue: separation of soluble proteins by two-dimensional polyacrylamide gel electrophoresis and identification by mass spectrometry. Electrophoresis 2002;23:2513–2524.CrossRefPubMedGoogle Scholar
  5. 5.
    Steel LF, Mattu TS, Mehta A et al. A proteomic approach for the discovery of early detection markers of hepatocellular carcinoma. Dis Markers 2001;17:179–189.PubMedGoogle Scholar
  6. 6.
    Aebersold R, Mann M. Mass spectrometry–based proteomics. Nature 2003;422:198–207.CrossRefPubMedGoogle Scholar
  7. 7.
    Vital Statistics of Japan. Statistics and Information Department, Ministers Secretariat, Ministry of Health, Labor and Welfare of Japan, 2003:25.Google Scholar
  8. 8.
    Kuramitsu Y, Nakamura K. Current progress in proteomic study of hepatitis C virus–related human hepatocellular carcinoma. Expert Rev Proteomics 2005;2:589–601.CrossRefPubMedGoogle Scholar
  9. 9.
    Kuramitsu Y, Nakamura K. Proteomic analysis of cancer tissues: shedding light on carcinogenesis and possible biomarkers. Proteomics 2006:6:5650–5661.CrossRefPubMedGoogle Scholar
  10. 10.
    O'Farrell PH. High-resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975: 250:4007–4021.PubMedGoogle Scholar
  11. 11.
    Latner AL, Marshall T, Gambie M. A simplified technique of high-resolution two-dimensional electrophoresis: serum immunoglobulins. Clin Chim Acta 1980;103:51–59.CrossRefPubMedGoogle Scholar
  12. 12.
    Unlu M., Morgan ME, Minden JS. Difference gel electrophoresis: a single-gel method for detecting changes in protein extracts. Electrophoresis 1997:18:2071–2077.CrossRefPubMedGoogle Scholar
  13. 13.
    Tonge R, Shaw J, Middleton B et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001:1:377–396.CrossRefPubMedGoogle Scholar
  14. 14.
    Shaw J, Rowlinson R, Nickson J et al. Evaluation of saturation labelling two-dimensional difference gel electrophoresis fluorescent dyes. Proteomics 2003:3;1181–1195.CrossRefPubMedGoogle Scholar
  15. 15.
    Kondo T, Seike M, Mori Y et al. Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool. Proteomics 2003;3:1758–1766.CrossRefPubMedGoogle Scholar
  16. 16.
    Gygi SP, Rist B, Gerber SA et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999:17;994–999.CrossRefPubMedGoogle Scholar
  17. 17.
    Wu WW, Wang G, Baek SJ et al. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 2006;5:651–658.CrossRefPubMedGoogle Scholar
  18. 18.
    Kuramitsu Y, Harada T, Takashima M et al. Increased expression, and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues of patients infected with hepatitis C virus. Electrophoresis 2006;27:1651–1658.CrossRefPubMedGoogle Scholar
  19. 19.
    Takashima T, Kuramitsu Y, Yokoyama Y et al. Overexpression of alpha-enolase in hepatitis C virus–related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 2005;5:1686–1692.CrossRefPubMedGoogle Scholar
  20. 20.
    Yokoyama Y, Kuramitsu Y, Takashima T et al. Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics 2004:4:2111–2116.CrossRefPubMedGoogle Scholar
  21. 21.
    Takashima T, Kuramitsu Y, Yokoyama Y et al. Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus–related hepatocellular carcinoma. Proteomics 2003:3: 2487–2493.CrossRefPubMedGoogle Scholar
  22. 22.
    Harada T, Kuramitsu Y, Makino A et al. Expression of tropomyosin alpha-4 chain is increased in esophageal squamous cell carcinoma as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography–mass spectrometry/mass spectrometry. Proteomics Clinical Applications 2007;1:215--223.Google Scholar
  23. 23.
    Mikuriya K, Kuramitsu Y, Ryozawa S et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography–mass spectrometry/mass spectrometry. Int J Oncol 2007;30:849–855.PubMedGoogle Scholar
  24. 24.
    Takashima T, Kuramitsu Y, Yokoyama Y et al. Proteomic analysis of auto-antibodies in patients with hepatocellular carcinoma. Proteomics 2006;6:3894–3900.CrossRefPubMedGoogle Scholar
  25. 25.
    Park KS, Cho SY, Kim H et al. Proteomic alterations of the variants of human aldehyde dehydrogenase isozymes correlate with hepatocellular carcinoma. Int. J. Cancer 2002;97:261–265.CrossRefPubMedGoogle Scholar
  26. 26.
    Kim J, Kim SH, Lee SU et al. Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization–mass spectrometry for identification of disease-related proteins. Electrophoresis 2002;23:4142–4156.CrossRefPubMedGoogle Scholar
  27. 27.
    Lim SO, Park SJ, Kim W et al. Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun 2002;291:1031–1037.CrossRefPubMedGoogle Scholar
  28. 28.
    Li C, Hong Y, Tan YX et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol Cell Proteomics 2004;3:399–409.CrossRefPubMedGoogle Scholar
  29. 29.
    Fujii K, Kondo T, Yokoo H et al. Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye. Proteomics 2005;5: 1411–1422.CrossRefPubMedGoogle Scholar
  30. 30.
    Zeindl-Eberhart E, Haraida S, Liebmann S et al. Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology 2004;39:540–549.CrossRefPubMedGoogle Scholar
  31. 31.
    Kim W, Oe Lim S, Kim JS et al. Comparison of proteome between hepatitis B virus– and hepatitis C virus–associated hepatocellular carcinoma. Clin. Cancer Res 2003;9:5493–5500.PubMedGoogle Scholar
  32. 32.
    Park KS, Kim H, Kim NG et al. Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Hepatology 2002;35:1459–1466.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhou G, Li H, DeCamp D et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002;1:117–123.CrossRefPubMedGoogle Scholar
  34. 34.
    Emmert-Buck MR, Gillespie JW, Paweletz CP et al. An approach to proteomic analysis of human tumors. Mol Carcinog 2000;27:158–165.CrossRefPubMedGoogle Scholar
  35. 35.
    Zhang L, Ying W, Mao Y et al. Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol 2003;9:650–654.PubMedGoogle Scholar
  36. 36.
    Shen J, Person MD, Zhu J et al. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004;64:9018–9026.CrossRefPubMedGoogle Scholar
  37. 37.
    Fujita Y, Nakanishi T, Hiramatsu M et al. Proteomics-based approach identifying auto-antibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006;12:6415–6420.CrossRefPubMedGoogle Scholar
  38. 38.
    Hong S, Misek DE, Wang H et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004;64:5504–5510.CrossRefPubMedGoogle Scholar
  39. 39.
    Le Naour F, Brichory F, Misek DE et al. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 2002;1:197–203.CrossRefPubMedGoogle Scholar
  40. 40.
    Hasegawa N, Mizutani K, Suzuki T et al. A comparative study of protein profiling by proteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells. Urol Int 2006;77:347–354.CrossRefPubMedGoogle Scholar
  41. 41.
    Strong R, Nakanishi T, Ross D et al. Alterations in the mitochondrial proteome of adriamycin-resistant MCF-7 breast cancer cells. J Proteome Res 2006;5:2389–2395.CrossRefPubMedGoogle Scholar
  42. 42.
    Le Moguen K, Lincet H, Deslandes E et al. Comparative proteomic analysis of cisplatin-sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1–R10. Proteomics 2006;6:5183–5192.CrossRefPubMedGoogle Scholar
  43. 43.
    Smith L, Lind MJ, Welham KJ et al. Cancer proteomics and its application to discovery of therapy response markers in human cancer. Cancer 2006;107:232–241.CrossRefPubMedGoogle Scholar
  44. 44.
    Liu Y, Liu H, Han B et al. Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 2006;66:3248–3255.CrossRefPubMedGoogle Scholar
  45. 45.
    Mori-Iwamoto S, Kuramitsu Y, Ryozawa S et al. A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Molecular Medicine Reports 2008;1:429–434.Google Scholar
  46. 46.
    Mori-Iwamoto S, Kuramitsu Y, Ryozawa S et al. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. International Journal of Oncology 2007;31:1345–1350.PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Yasuhiro Kuramitsu
    • 1
  • Kazuyuki Nakamura
    • 1
  1. 1.Department of Biochemistry and Functional ProteomicsYamaguchi University Graduate School of MedicineYamaguchiJapan

Personalised recommendations